MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing an AI-powered voice analysis platform designed to rapidly detect drug and alcohol impairment from short speech samples, offering a non-invasive alternative to traditional testing methods. The technology, trained on more than 50 million data points and analyzing over 140 acoustic markers, aims to deliver real-time impairment assessments through Edge AI kiosks. Initial field testing is planned for 2026, with an initial commercial focus on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges.
The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry forecasts. MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers, and healthcare, leveraging its proprietary research to address increasing demand for faster, scalable workplace impairment detection. The company's AI prediction model uses voice analysis to predict alcohol intoxication with remarkable accuracy, as detailed in the full article at https://ibn.fm/Gw5Fa.
MindBio is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for detection in various environments, including mining, aviation, construction, and law enforcement. For more information, visit the company's newsroom at https://ibn.fm/MBQIF.
